ADPT Adaptive Biotechnologies Corp

Price (delayed)

$8.22

Market cap

$1.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.63

Enterprise value

$1.17B

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the ...

Highlights
The revenue has grown by 33% YoY
The quick ratio has dropped by 51% year-on-year but it is up by 3.4% since the previous quarter
The gross profit has grown by 15% year-on-year but it has declined by 2.9% since the previous quarter
The company's net income fell by 48% YoY and by 11% QoQ
ADPT's EPS is down by 43% year-on-year and by 10% since the previous quarter

Key stats

What are the main financial stats of ADPT
Market
Shares outstanding
142.23M
Market cap
$1.17B
Enterprise value
$1.17B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.1
Price to sales (P/S)
7.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.54
Earnings
Revenue
$154.52M
EBIT
-$229.37M
EBITDA
-$205.95M
Free cash flow
-$247.92M
Per share
EPS
-$1.63
Free cash flow per share
-$1.75
Book value per share
$3.91
Revenue per share
$1.09
TBVPS
$5.16
Balance sheet
Total assets
$858.19M
Total liabilities
$304.94M
Debt
$113.52M
Equity
$553.21M
Working capital
$304.05M
Liquidity
Debt to equity
0.21
Current ratio
3.64
Quick ratio
3.38
Net debt/EBITDA
0.02
Margins
EBITDA margin
-133.3%
Gross margin
66%
Net margin
-148.4%
Operating margin
-149.3%
Efficiency
Return on assets
-24.1%
Return on equity
-36.7%
Return on invested capital
-33.9%
Return on capital employed
-30.9%
Return on sales
-148.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADPT stock price

How has the Adaptive Biotechnologies stock price performed over time
Intraday
-0.24%
1 week
6.06%
1 month
0%
1 year
-80.52%
YTD
-70.71%
QTD
-40.78%

Financial performance

How have Adaptive Biotechnologies's revenue and profit performed over time
Revenue
$154.52M
Gross profit
$102.02M
Operating income
-$230.75M
Net income
-$229.37M
Gross margin
66%
Net margin
-148.4%
The company's net income fell by 48% YoY and by 11% QoQ
Adaptive Biotechnologies's operating income has decreased by 45% YoY and by 10% QoQ
The revenue has grown by 33% YoY
The gross profit has grown by 15% year-on-year but it has declined by 2.9% since the previous quarter

Growth

What is Adaptive Biotechnologies's growth rate over time

Valuation

What is Adaptive Biotechnologies stock price valuation
P/E
N/A
P/B
2.1
P/S
7.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.54
ADPT's EPS is down by 43% year-on-year and by 10% since the previous quarter
ADPT's P/B is 67% below its last 4 quarters average of 6.4
ADPT's equity is down by 24% year-on-year and by 8% since the previous quarter
ADPT's price to sales (P/S) is 73% lower than its last 4 quarters average of 28.5
The revenue has grown by 33% YoY

Efficiency

How efficient is Adaptive Biotechnologies business performance
The ROE has shrunk by 64% YoY and by 18% QoQ
Adaptive Biotechnologies's ROA has plunged by 61% YoY and by 17% from the previous quarter
The ROIC has contracted by 28% YoY and by 17% from the previous quarter
ADPT's return on sales is down by 11% year-on-year and by 10% since the previous quarter

Dividends

What is ADPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADPT.

Financial health

How did Adaptive Biotechnologies financials performed over time
The total assets is 181% more than the total liabilities
The quick ratio has dropped by 51% year-on-year but it is up by 3.4% since the previous quarter
The current ratio has contracted by 49% YoY but it has grown by 2.8% from the previous quarter
ADPT's debt is 79% smaller than its equity
ADPT's debt to equity has surged by 50% year-on-year and by 11% since the previous quarter
ADPT's equity is down by 24% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.